Zymergen
Zymergen raises $575M Series D at $3.2B valuation
Zymergen: Series D Funding Round
Zymergen has successfully raised $575M in Series D funding, reaching a valuation of $3.2B.
Company Overview
Bio-based materials manufacturing
Funding Details
The Series D round was led by SoftBank Vision Fund, with participation from DCVC, True Ventures, Data Collective, Two Sigma Ventures.
Company Information
- Headquarters: 5980 Horton Street, Emeryville, CA 94608
- Founded: 2013
- Employees: 800+
- Category: Biotech
Investment
Zymergen plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- SoftBank Vision Fund: Verified investor in Series D
- DCVC: Verified investor in Series D
- True Ventures: Verified investor in Series D
- Data Collective: Verified investor in Series D
- Two Sigma Ventures: Verified investor in Series D
Company Info
Investors (5)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free